Effect of semaglutide with metformin for weight loss and fertility in polycystic ovary syndrome (PCOS) patients with obesity: A pilot prospective study
Abstract
BACKGROUND AND AIMS: Polycystic ovary syndrome (PCOS) and obesity increase the risk of infertility, preterm birth and birth of a hypertrophic neonate. Effective weight loss can improve this disorder. The aim of this study was to evaluate the effect of subcutaneous semaglutide in combination with metformin for the treatment of PCOS patients with obesity and prediabetes.
PATIENTS AND METHODS: We prospectively enrolled 20 consecutive PCOS patients with obesity and prediabetes, (mean age 32 years) with BMI 34.8 ± 4.3 kg/m2, on combination therapy with metformin 1000 mg daily and subcutaneous semaglutide 0.25-0.5 mg weekly. Patients were followed up for 6 months. All patients were clinically examined and human body composition (lean mass, fat) as well as weight were measured by bioelectrical impedance analysis InBody 370.
RESULTS: There was a significant weight reduction after 5 months of therapy (98.4 ± 15.5 vs. 85.5 ± 16.6 kg, p < 0.05), and a reduction was observed in BMI (34.8 ± 4.3 vs. 30.2 ± 4.7 kg/m2, p < 0.05). Similarly, there was also a significant reduction of fat mass (41.3 ± 10.8 vs. 32.3 ± 10.3, p < 0.05), but no impact of therapy on lean mass (31.1 ± 4.5 vs. 29.1 ± 5.1 kg, p = 0.56). Within the follow-up period, a significant improvement in fertility was observed, with 60 % of the patients treated achieving pregnancy. All resulting pregnancies culminated in the delivery of eutrophic neonates.
CONCLUSION: In this study, we demonstrated a significant efficacy of…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 20 participants or records.
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.